• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Prescription Drug Prices: Analysis of Canada's Patented Medicine Prices ReviewBoard
【24h】

Prescription Drug Prices: Analysis of Canada's Patented Medicine Prices ReviewBoard

机译：处方药价格：加拿大专利药价审查分析

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

As public concern about health care costs intensifies, the escalation inprescription drug costs--borne by consumers, insurers, and other third-party payers--has spurred congressional interest in ways to curb the growth of prescription drug prices. The 102nd Congress introduced at least 11 bills to constrain drug prices, yet none of these was enacted. To monitor prescription drug pricing, some of these bills would have created a federal board, modelled after Canada's Patented Medicine Prices Review Board. In a recent study, the authors found that manufacturers charge less for many drugs in Canada than in the United States and that the Canadian approach to regulating drug prices contributes to this price differential. You asked that we (1) describe the purpose and structure of Canada's Patented Medicine Prices Review Board as well as its guidelines and procedures, especially those used to determine if a drug price is excessive, and (2) summarize the evidence about the effects of the Board's actions in Canada on the prices of new drugs, on price increases for existing drugs, and on pharmaceutical research and development (R&D).

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号